Here are the top 5 articles for the month of June.
Hi, this is Jaime Rosenberg for The American Journal of Managed Care®. Here are the top 5 articles for the month of June.
Number 5: The final morning of the American Diabetes Association (ADA) Scientific Sessions featured cardiovascular and renal results from recent trials involving type 2 diabetes drugs, including CREDENCE, the first dedicated renal outcomes trial for a type 2 diabetes therapy.
Number 4: Although multiple cancers are attributable to the human papillomavirus, or HPV, uptake of the vaccine remains low 13 years after it was first introduced. Among the populations that should be vaccinated in the United States, only 49% actually receive the vaccine.
Number 3: During ASCO’s annual meeting, the organization held a town hall to discuss the topic of drug pricing, which brought tense conversation about the subject.
Number 2: An analysis of phase 3 trial data for investigational type 2 diabetes drug oral semaglutide showed that GLP-1 receptor agonist does a better job reducing blood sugar than leading SGLT2 inhibitor empagliflozin.
Number 1: Findings from ADA showed that the type 2 diabetes drug dapagliflozin significantly reduced the risk of renal decline, kidney failure, and renal death.
To read all of these articles and more, visit ajmc.com.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Real-World Data Show Leqvio's Effectiveness in Reducing LDL-C in Patients With ASCVD
April 11th 2024Results from the V-INITIATE trial showed a substantial 60% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 in the inclisiran first group compared with a mere 7% reduction in the usual care group.
Read More